Authors: David R Luke, Karen Ka Yan Lee, Anne Kizy, Daisy Sun, Ronald Harris, Tyler D Luke, Conroy Cheng.
Background/Purpose: Treatment of Type 2 diabetes (T2D) remains an unmet need, particularly a medication with low toxicity. BTI320 (SugarDown®) is fractionated galactomannan with inhibitory activity on carbohydratehydrolyzing enzymes. The primary objective of this study was to investigate the efficacy and safety of BTI320 on glycemic control in T2D.
Subjects/Methods: This was a double-blind, placebo-controlled, multi-center study in 60 T2D adults. Subjects ingested 4 g BTI320 or placebo 10 minutes before meals 3 times daily for 12 weeks. The primary endpoint was the change from Baseline to Week 12 in 2-hr post-prandial glucose (PPG) AUC between groups.
Results/Conclusion: A consistent trend was observed in favor of BTI320 vs. placebo in change from Baseline at Week 12 in 2-hr PPG AUC (-795.00 vs. -228.75 mg/dL*min), HbA1c (-0.7% vs. +1.1%), lipids, weight/BMI, and blood pressure. At Week 12, BTI320 had more subjects with stable glucose levels (84.6% vs. 79.2%). According to CGM, the BTI320 group had more subjects with stable glucose levels (84.6 vs. 79.2%) and BTI320 subjects experienced relative hypoglycemia for shorter duration than placebo consistently across all visits. No differences were observed in AE profiles between groups. BTI320 was proven to be efficacious and safe in T2D.
This study is registered at ClinicalTrials.gov (NCT03655535).
View/Download pdf